Alps Advisors Inc. boosted its stake in Chimerix Inc. (NASDAQ:CMRX) by 25.1% during the second quarter, Holdings Channel reports. The institutional investor owned 64,919 shares of the biopharmaceutical company’s stock after buying an additional 13,023 shares during the period. Alps Advisors Inc.’s holdings in Chimerix were worth $255,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. UBS Asset Management Americas Inc. raised its stake in Chimerix by 5.1% in the first quarter. UBS Asset Management Americas Inc. now owns 3,256,191 shares of the biopharmaceutical company’s stock valued at $16,640,000 after buying an additional 156,969 shares in the last quarter. A.R.T. Advisors LLC raised its stake in Chimerix by 3,008.7% in the first quarter. A.R.T. Advisors LLC now owns 866,059 shares of the biopharmaceutical company’s stock valued at $4,425,000 after buying an additional 838,200 shares in the last quarter. Opaleye Management Inc. purchased a new stake in Chimerix during the first quarter valued at about $3,449,000. Geode Capital Management LLC raised its stake in Chimerix by 1.0% in the first quarter. Geode Capital Management LLC now owns 286,085 shares of the biopharmaceutical company’s stock valued at $1,461,000 after buying an additional 2,755 shares in the last quarter. Finally, Sabby Management LLC purchased a new stake in Chimerix during the first quarter valued at about $274,000. Institutional investors and hedge funds own 66.12% of the company’s stock.
Shares of Chimerix Inc. (NASDAQ:CMRX) traded down 3.62% during trading on Friday, reaching $4.52. 323,955 shares of the company were exchanged. The stock’s market capitalization is $208.89 million. Chimerix Inc. has a one year low of $3.49 and a one year high of $43.37. The stock has a 50-day moving average price of $5.16 and a 200-day moving average price of $4.79.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.12. The firm earned $1.80 million during the quarter, compared to analyst estimates of $1.98 million. Chimerix had a negative net margin of 1,356.50% and a negative return on equity of 34.75%. Analysts forecast that Chimerix Inc. will post ($1.78) EPS for the current year.
A number of analysts have weighed in on the stock. FBR & Co restated a “hold” rating on shares of Chimerix in a research report on Sunday, July 17th. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Wednesday, August 10th. JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 target price on shares of Chimerix in a research report on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the company a “buy” rating in a research report on Thursday, August 18th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $12.38.
In related news, insider M Michelle Berrey bought 22,417 shares of the stock in a transaction dated Monday, August 29th. The stock was purchased at an average cost of $4.47 per share, with a total value of $100,203.99. Following the completion of the purchase, the insider now owns 281,238 shares of the company’s stock, valued at $1,257,133.86. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John M. Leonard sold 5,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.03, for a total transaction of $25,150.00. The disclosure for this sale can be found here. Insiders own 10.50% of the company’s stock.
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.